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Abstract
Background: Depressive symptoms are common in older adults. The effectiveness of pharmacological treatments
and the availability of psychological treatments in primary care are limited. A behavioural approach to depression
treatment might be beneficial to many older adults but such care is still largely unavailable. Behavioural Activation
(BA) protocols are less complicated and more easy to train than other psychological therapies, making them very
suitable for delivery by less specialised therapists. The recent introduction of the mental health nurse in primary
care centres in the Netherlands has created major opportunities for improving the accessibility of psychological
treatments for late-life depression in primary care. BA may thus address the needs of older patients while improving
treatment outcome and lowering costs.The primary objective of this study is to compare the effectiveness and
cost-effectiveness of BA in comparison with treatment as usual (TAU) for late-life depression in Dutch primary care.
A secondary goal is to explore several potential mechanisms of change, as well as predictors and moderators of
treatment outcome of BA for late-life depression.
Methods/design: Cluster-randomised controlled multicentre trial with two parallel groups: a) behavioural
activation, and b) treatment as usual, conducted in primary care centres with a follow-up of 52 weeks. The main
inclusion criterion is a PHQ-9 score > 9. Patients are excluded from the trial in case of severe mental illness that
requires specialized treatment, high suicide risk, drug and/or alcohol abuse, prior psychotherapy, change in dosage
or type of prescribed antidepressants in the previous 12 weeks, or moderate to severe cognitive impairment. The
intervention consists of 8 weekly 30-min BA sessions delivered by a trained mental health nurse.
Discussion: We expect BA to be an effective and cost-effective treatment for late-life depression compared to TAU.
BA delivered by mental health nurses could increase the availability and accessibility of non-pharmacological
treatments for late-life depression in primary care.
Trial registration: This study is retrospectively registered in the Dutch Clinical Trial Register NTR6013 on
August 25th 2016.
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Background
With a point prevalence of 13,4% clinically relevant late-
life depressive syndromes are common [1, 2]. A study in
Dutch primary care practices found that major depression
was prevalent in 13,7% and minor depression in 10,2% of
the elderly patients [3]. However, most older patients with
depression remain untreated [4]. Often older adults attri-
bute their depressive symptoms to the ageing process or
declining physical health [5–7], have low expectations
about existing treatments [6], and/or feel adversity
towards treatment in mental health clinics [8]. A large
3-year longitudinal cohort study on late-life depression in
32 Dutch primary care centres (PCC’s) showed the
prognosis to be poor [9]. The direct economic costs of
depression treatment as well as the indirect costs of
depression associated with premature mortality and
morbidity are high, as people with depression have a
higher healthcare consumption than non depressed
people [10–12]. The increasing ageing population in the
Netherlands will raise healthcare costs and un(der)treated
older patients with clinical depression will add to the
burden.
Although late-life depression can be treated effect-
ively, there is space for both improvement and devel-
opment of alternative treatments [9, 13, 14].
Furthermore, especially in older adults, the use of
psychoactive agents like antidepressants is associated
with risks and adverse events, such as falls and ad-
verse interactions with somatic medications [2, 15,
16]. Although older adults prefer psychological treat-
ment over pharmacological treatment [1], only 3% of
older patients with minor depression and 10% of
older patients with major depressive disorder are re-
ferred to a mental health professional [15]. There are
several barriers that can explain this underutilization
of mental health services [17]. Older adults report a
fear of stigmatization and have difficulties identifying
their need for help, believing that their symptoms are
normal [17]. Furthermore, there is a lack of psycho-
therapists trained in treating older adults and most
facilities treating older patients for depression are lo-
cated outside the PCCs [8]. Patients thus experience
practical barriers such as transportation problems and
are held back by the costs of treatment [13, 16, 17].
Many of these barriers could be overcome if an ef-
fective psychological treatment was available in pri-
mary care, one that acknowledges but does not
medicalize the depressive feelings older adults experi-
ence. Behavioural activation (BA) might be that
treatment.
BA aims to create a personal environment of positive
reinforcement by increasing functional and pleasurable
behaviour, and by decreasing avoidant and depressed
behaviour [18, 19]. BA protocols are less complex, easier
to train and to implement than other psychological
therapies, making them very suitable for implementation
in primary care, as studies from the UK have already
shown for non-older adults [20, 21]. Currently, cognitive
behavioural therapy (CBT) and interpersonal therapy
(IPT) are the most frequently used treatments for de-
pression, but research suggests that BA might be equally
effective [22–25]. Recent introduction of the mental
health nurse (MHN) in PCCs in the Netherlands has
created major opportunities for the delivery of psycho-
logical treatments, such as BA, for late-life depression.
The availability of BA in PCCs may improve accessibility
and acceptability of psychological treatment for older
patients [8]. BA may thus address the needs of older pa-
tients while improving treatment outcome and lowering
costs [1, 26].
Effectiveness of BA
Several meta-analyses [27, 28] as well as a recent RCT
[24] among depressed patients found BA to be at least
equivalent to CBT in the acute phase and at follow-up,
and more effective than control conditions and some
other psychological therapies for depression in adults.
Moreover, MHN-delivered BA is both feasible, effective
and cost-effective in managing depression in primary
care [20, 21].
Meta-analyses with respect to BA treatment for
late-life depression confirm its benefits for this age-
group, although included studies were small and had
low methodological quality [29–31]. Furthermore, two
small observational studies showed that BA delivered
by master level students and by social workers is
feasible [32, 33].
Further evidence for the effectiveness of BA for late-
life depression stems from a large RCT on care man-
agement for patients with late-life depression that sug-
gest that activity scheduling, which exhibits similarities
with BA, could be a major contributor to treatment
gains [34]. This trial did not directly compare BA and
TAU. In another RCT ‘collaborative care’ BA was the
principal treatment compared to TAU for older adults
with subclinical depressive symptoms. The study found
a small to medium effect of collaborative care on de-
pressive symptoms compared to TAU [35]. In both
studies, BA was only a component of a new care man-
agement plan, so the direct effects of BA on depressive
symptoms could not be determined.
Despite the growing evidence of the effectiveness of
BA in managing depression, no methodologically sound
and well-conducted studies have evaluated the effective-
ness and cost-effectiveness of BA by MHNs as a stand-
alone treatment for older depressed adults in primary
care. BA, delivered by MHNs, could increase the
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availability and accessibility of non-pharmacological
treatments for late-life depression in primary care.
Mechanisms, predictors and moderators
As stated before, recent studies show that BA is non-
inferior to CBT in adults [22]. Several other studies
suggest that most psychological interventions for de-
pression are equally effective, a phenomenon also re-
ferred to as the “dodo-bird verdict” [36, 37]. This
doesn’t mean that all interventions are equally effect-
ive for all patients. Therefore we are specifically inter-
ested in the underlying mechanisms and predictors
that can explain how therapeutic change comes about
in BA.
BA theory suggests that changes in activation cause
and precede the decline of depressive symptoms [18,
19, 38]. This has been demonstrated in a recent small
scaled study that found that changes in activation pre-
ceded or co-occurred with changes in depression in
adults, while in TAU this pattern was not found [39].
Another potential therapy-specific mechanism of BA is
rumination. In BA, rumination is specifically targeted
as a behavioural problem that can be actively tackled
with behavioural interventions. BA attempts to change
the act of rumination, thereby leaving more time for
constructive and social behaviour, rather than challen-
ging the content of the dysfunctional thoughts [18].
Several non-specific factors that are potentially re-
lated to treatment gain in depression as well as po-
tential predictors of the (differential) effects are also
investigated, such as loneliness, physical activity,
cognitive functioning, therapeutic alliance, behavioural
limitations, general psychopathology and treatment
expectations [40–43].
Objectives and hypotheses
In the current trial, we aim to evaluate the effectiveness
and cost-effectiveness of BA, delivered by mental health
nurses for older adults with moderate to severe depres-
sive symptoms in PCCs. The study will investigate the
effectiveness of BA in real life primary health care, with
the aim to generalize results to primary care in the
Netherlands and abroad.
The second aim of this study is to investigate whether
treatment gains in BA can be explained by treatment-
specific factors based on BA-theory, such as the degree
of activation, or non-specific factors, such as the thera-
peutic alliance or treatment expectations. An example of
a possible mechanistic pathway that might explain the
effectiveness of BA can be seen in Fig. 1.
The following main research questions were formulated:
1. What is the effectiveness of BA compared to TAU
for older adults with clinically relevant depressive
symptoms over the course of 12 months?
2. What is the cost-effectiveness of BA compared to
TAU from a societal perspective for older adults
with clinically relevant depressive symptoms, over
the course of 12 months?
3. What are the mechanisms of change that account
for the effectiveness of BA compared to TAU?
Fig. 1 Theoretical framework for potential mechanisms of action
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4. What are the predictors and moderators of outcome
of BA compared to TAU?
In line with previous research, we hypothesize that BA
is more effective and cost-effective than TAU [21–31].
Methods
Study design
The design of this study is a cluster randomized controlled
multicentre trial with two parallel treatment groups with a
follow up of 52 weeks. The treatment conditions are
behavioural activation (BA), and treatment as usual
(TAU). Data are collected at general practices in the
South-Eastern region of the Netherlands. Only practices
that employ a mental health nurse (MHN) are included.
Currently, more than 80% of Dutch PCCs employ an
MHN [44]. A list of currently participating PCCs can be
found on http://beatdepressie.nl/voor-deelnemers/. We
will report the study according to the SPIRIT guidelines
[45]. The study has been approved by the local medical
ethical committee of the Radboud University Medical
Centre (CMO Arnhem-Nijmegen).
Eligibility criteria
General practitioners and mental health nurses are
responsible of the recruitment of participants. They
include eligible patients during consultations (see proce-
dures for details). We will include 200 older adults
(≥65 years). All patients presenting with depressive
symptoms or depression are asked to participate. Those
who have a PHQ-9 score > 9 and have given informed
consent will be included in the study. Patients will be ex-
cluded from the trial in the case of 1) current severe
mental illness in need of specialized treatment, including
bipolar disorder, obsessive-compulsive disorder, (history
of ) psychosis, high risk of suicide, drug and/or alcohol
abuse, 2) psychotherapy in the previous 12 weeks or
current treatment by a mental health specialist and 3)
moderate to severe cognitive impairment. Patients with
antidepressants are eligible provided that a stable dose
has been maintained for at least 12 weeks before partici-
pating in the study.
Interventions
BA aims to increase activation levels by helping patients
engage in rewarding activities and reduce avoidance
behaviour that diminishes distress in the short term but
has adverse consequences in the long term [18]. Our BA
protocol is based on the model developed by Martell
and colleagues [18]. This original BA model consists of
12 to 24 one-hour sessions and is designed for patients
referred to specialised mental healthcare institutions for
treatment. The patients eligible for treatment in PCCs
will be a more mixed population suffering from clinically
relevant depressive symptoms although less severe than
patients referred to specialist care. In studies on collabora-
tive care for depressed older adults, BA-treatment by
MHNs is delivered in 8 to 10 15–45 min sessions [34, 35].
We decided to adjust BA intensity to a level that would fit
the contemporary Dutch model for MHN-delivered care
in PCCs.
BA will be delivered in eight 30-min face-to-face ses-
sions within eight weeks, with the first session lasting
45 min. All key elements of the original BA-protocol of
Martell et al. are kept in, including a functional analysis,
activity registration, activity scheduling and relapse pre-
vention [46]. Prior to the start of the study, all MHNs of
the BA group received a two-day training by licensed
specialists on the use of the BA protocol. While treating
patients, MHNs receive two-weekly online (skype)
supervision in groups of three, led by one of the BA
specialists that provided the training. MHNs fill in a ses-
sion checklist for every patient to check for therapy
adherence.
Treatment as usual (TAU) will be unrestricted and
involves the GPs treatment options consistent with the
guidelines of the Dutch College of GPs [47, 48]. At base-
line GPs indicate their intended treatment, such as
pharmacological treatment, psychological treatment by a
MHN or a psychologist, or watchful waiting. At post-
treatment GPs confirm whether the intended treatment
plan was followed and which changes were made.
Although activation is addressed as an advice to patients
suffering from depression or depressive symptoms in the
before mentioned guidelines, it is not offered as a sys-
tematic and protocolised intervention and therefore not
comparable to the BA protocol adopted in our study.
Procedure
Older adults that visit their GP with depressive symptoms,
complaints of loneliness, reduced social functioning, med-
ically unexplained symptoms, and/or frequent attenders
without a clear somatic diagnosis will be screened for po-
tential eligibility. If the GP or MHN suspects depressive
symptoms or if the patient fulfils one of the aforemen-
tioned criteria, the GP or MHN will screen the patient
with the first two questions of Mini International Neuro-
psychiatric Interview (M.I.N.I. 5.0.0.) [49] on depressive
symptoms. If one or both of the questions is answered
affirmatively, the GP will provide the patient with basic
information about the study and will ask whether (s)he
agrees to be contacted by our research assistant.
Eligible participants receive a letter with study infor-
mation and are contacted by a research assistant to plan
a baseline visit, that takes place approximately one week
after they’ve received the letter. This will allow them to
make an informed decision about their participation. At
the baseline visit a research assistant will visit the patient
Janssen et al. BMC Psychiatry  (2017) 17:230 Page 4 of 11
at home to assess whether (s)he fulfils the inclusion
criteria and is willing to participate. During this visit,
also several cognitive tests will be performed, and the
presence of depressive disorder will be established with a
semi-structured clinical interview M.I.N.I. 5.0.0 [49].
After the baseline meeting, the patient will receive the
online or paper-pencil baseline questionnaire, which
they will be asked to complete within the following
week. Furthermore, the patient will wear an accelerom-
eter for one week. Approximately one week after the
baseline meeting the BA- or TAU-treatment is started.
During the treatment phase (baseline to 9 weeks),
patients in both research conditions will receive a ques-
tionnaire every two to four weeks at home. BA patients
also fill in a short questionnaire during the weekly
sessions with the MHN. Nine weeks after the baseline
assessment, patients will receive a call from a research
assistant for the post-treatment assessment consisting of
two cognitive tests, as well as a short interview to estab-
lish the presence of depressive disorder. After this,
patients will wear the accelerometer for another week,
and complete the post-treatment questionnaire within
that week.
In the follow-up period (3 to 12 months after base-
line), patients will receive a follow-up questionnaire
every three months. After twelve months the last follow-
up home-visit by a research assistant will be planned.
For a detailed schedule of all measurements per time-
point, see Table 1.
Outcomes
Clinical outcome measures
Depressive symptoms
The Quick Inventory of Depressive Symptomatology
(QIDS-SR) will be used as the primary outcome measure
of depressive severity. The QIDS-SR is a 16-item self-
report instrument assessing depressive symptoms during
the last two weeks. It can be administered in 5–7 min
and has good psychometric properties [48].
The Patient Health Questionnaire- 9 (PHQ-9) is a 9-
item self-report instrument assessing depressive symptoms
during the last week. It will be used as a secondary out-
come measure and to assess changes in depressive symp-
toms over the course of treatment. The psychometric
properties of the PHQ-9 are good [50, 51]. Patients scoring
Table 1 Participant timeline
Treatment phase (weekly) Follow up (3 monthly)
Measuresa -1 0 1 2 3 4 5 6 7 8 3 6 9 12
Clinical outcome measures
Depression (PHQ-9)b • • • • • • • • • • • • •
Mini 5.0 (2 questions) •
MINI 5.0 interview (baseline complete, T8 only depression) • •
Cognitive (MoCA) • •
Depression (QID-S) • • • • • •
Well- being & moodc (visual analogue scale) • • • • • • • •
Psychopathology (BSI-SF) • • •
Limitations (WHODAS) • • •
Process BA-specific
Behavioural activity (BADS) • • • • • • • •
Physical activity (accelerometer) • •
Ruminative brooding (RRS) • • • • • • • •
Process general
Loneliness (S&ES) • • • • • • •
Therapeutic alliance (SRS)c • • • • • • • •
Cognitive (STROOP & DSST) • • •
Expectancy (Expectancy and credibility list)c •
Cost effectiveness
TIC-P • • • • •
EQ-5D • • • • • •
a− 1 = screening by GP, 0 = baseline measurement by research assistant, 8 = post-treatment measurement by research assistant badministered weekly in BA and
two-weekly in TAU. conly administered in BA
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PHQ-9 > 9 are classified as having clinically relevant
depressive symptoms [52].
Depressive disorder and psychiatric comorbidity
To distinguish patients with a major depressive disorder
(MDD) from patients with only clinically relevant symp-
toms a research assistant will administer the complete
Mini International Neuropsychiatric Interview (M.I.N.I.
5.0.0). Furthermore, this instrument assesses psychiatric
co-morbidity. The M.I.N.I. 5.0.0 is a short diagnostic
interview that assesses current psychological disorders,
based on DSM-IV diagnostic criteria. The reliability and
validity of the M.I.N.I are good [49]. The M.I.N.I. can be
administered in about 15 min [53].
Economic evaluation
Quality of life
Quality of life will be evaluated using the five level
version of the self-report EuroQol questionnaire (EQ-
5D-5 L) [54]. The EQ-5D-5 L consists of five health-
state dimensions on which respondents indicate their
perception of their health-related well-being. Each
dimension is rated as causing ‘no problems’, ‘slight prob-
lems’, ‘some problems’, ‘moderate problems’ or ‘extreme
problems’. The Dutch EQ-5D tariff will be used to calcu-
late Quality-Adjusted Life-Years (QALYs) [55]. The EQ-
5D-5 L appears to be a valid extension of the reliable
and valid EQ-5D-3 L [56].
Health care utilisation
Healthcare consumption and productivity losses will be
recorded every three months in both study conditions
using a modified version of the Trimbos and iMTA
questionnaire on Costs associated with Psychiatric illness
(TiC-P) [57]. Healthcare costs include the number of
consultations with health care providers, medication and
admissions to hospitals. Lost productivity costs are
defined as the productivity lost due to absenteeism from
(unpaid) work and reduced efficiency at work.
Process and predictor variables
Psychopathology
Psychopathology will be measured using the Brief Symp-
tom Inventory-18 (BSI-18) [58, 59]. The BSI-18 has
three subscales: depression, anxiety and somatic symp-
toms, that together make up the Global severity Index
(GSI) of psychological distress. Patients rate on a five-
point Likert scale how much they have been bothered by
each symptom in the last 7 days. The BSI-18 is a valid
and reliable measure for psychological distress, and can
detect depression and anxiety based on a DSM-IV classi-
fication in older adults [60].
Behavioural limitations
To assess the behavioural limitations that patient experi-
ence in daily life, The World Health Organization
Disability Assessment Schedule 2.0 (WHODAS, short
version) will be used [61]. The short version of the
instrument has 12 items on a 5-point Likert scale. The
instrument has proven to be able to measure the impact
of health conditions such as depression on daily life and
can monitor the effectiveness of interventions [62].
Cognitive functioning
To test baseline cognitive functioning the Montréal
Cognitive Assessment Scale (MoCA) is used. The MoCA
is a short cognitive screening tool that tests a wide range
of cognitive functions [63]. The tool has a high sensitiv-
ity as well as specificity for detecting mild cognitive im-
pairment, and is especially interesting for the population
of depressed elderly because it measures executive func-
tioning [63].
Behavioural activation
To measure perceived active behaviour in both BA and
TAU conditions the Behavioural Activation for Depres-
sion Scale (BADS) can be used. The BADS is a 25-item
self-report instrument measuring behavioural activation
[64]. Four domains of behavioural activation are distin-
guished: Activation, avoidance/rumination, work/school
impairment and social impairment. The work/school do-
main may seem less relevant for our population, but the
questions are formulated in such a way that they could
easily be applied to general responsibilities like house-
hold chores and volunteering. The psychometric proper-
ties of the BADS are good [64].
Rumination
To assess the extent of depressive brooding, the brood-
ing subscale of the Rumination Response Scale (RRS)
will be used [65–67]. The brooding scale consists of 5
questions on a 4-point Likert-scale. The reliability, and
convergent and discriminant validity of the brooding
scale are appropriate, and it predicts depressive symp-
toms prospectively [66].
Physical activity
The expected influence of BA on physical activity of de-
pressed participants can be objectively registered with an
accelerometer (DYnaPort MoveMonitor). Daily physical
activities will be measured over a 1-week period at the
start of the intervention and 10 weeks after baseline.
Participants will be asked to wear a sensor at their lower
back, by use of an elastic belt around their waist. The
amount of daily activities will be determined, based on
the MoveMonitor algorithms, which classifies the accel-
eration data into 4 types of activity: sitting, lying,
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standing and locomotion. Also, non-wearing time per
day will be detected. Subsequently, the duration of loco-
motion, lying, sitting, and standing, movement intensity,
the number of locomotion bouts and transitions to
standing, and the median and maximum duration of
locomotion will be calculated per day [68].
The quality of daily activities will be determined as the
median values of gait characteristics, calculated over all
episodes of locomotion during the week according to [69].
These characteristics include local divergence exponent,
inter-stride variability, and entropy. In addition, we will
determine the complexity of physical activity, based on
the concept of ‘barcoding’ [70]. Such a barcode reflects
different states of physical activity, based on features such
as type, intensity, and duration of lying, sitting, standing
and locomotion, and is quantified by structural complexity
metrics and sample entropy. The accelerometer can be
worn at all times except during water activities such as
swimming or showering. For a detailed schedule of the
timing of several measures, see Table 1.
Loneliness
The De Jong Gierveld Short Scale for emotional and
social loneliness, a 6-item self-report measure will be
used [71]. Patients answer three questions about social
loneliness, characterized by a smaller number of friends
than is considered desirable, and three questions about
emotional loneliness, characterized by a lack of intimacy
in current relationships, on a 6-point scale. The sum of
both subscales indicates overall loneliness. The Dutch
version of this short form has good psychometric prop-
erties [71].
Therapeutic alliance
To measure therapeutic alliance, the Session Rating
Scale (SRS) is the instrument of choice. It consists of 4
visual analogue scales and aims to measure the self-
reported therapeutic alliance by the patient [72]. The
psychometric properties of this instrument are satisfac-
tory and the feasibility in clinical practice is found to be
good [72].
Psychomotor performance
With the Digit Symbol Substitution Test (DSST) the de-
generation or improvement of psychomotor perform-
ance can be measured [73]. The DSST is pencil and
paper test in which the patient is given a combination of
numbers and matching symbols and a test section with
numbers and empty boxes. The patient is asked to fill as
many empty boxes as possible with a symbol matching
each number within 90 s.
Executive functioning
To measure whether behavioural activation is effective
regardless of the level of executive functioning of the pa-
tient, the Stroop-task will be used [74, 75]. Patients will
be presented with three different sheets of words and/or
colours. The first sheet contains colour names in black
ink. Patients are asked to read the colour names. The
second sheet consists of squares printed in different
colours. Patients are asked to name the colours on the
sheet. The last sheet contains the words “red”, “green”
and “blue” that are printed in sometimes the same (e.g.
the word red in red ink) and sometimes a different
colour ink. The task is to name the colour of the ink
in which the word is printed as quickly as possible.
The increase in time taken to perform the latter task
compared with the basic task is referred to as “the
Stroop interference effect”.
Treatment expectations
To asses treatment expectations, the credibility & ex-
pectancy questionnaire will be used [76]. The question-
naire consists of six questions that are assessed on a 9
point Likert-scale. The questionnaire appears to have
high internal consistency within each factor and good
test–retest reliability [77]. Expectancy measures will not
be used to ensure initial equivalence between two com-
pared treatments, but to measure individual differences
in expectancy within the BA group.
Sample size
Comparing the effects BA for depression to a waiting list
condition, Cuijpers et al. reported an effect size of 0.9 in
a meta-analysis [27]. Since we will be comparing BA to a
more active treatment condition (TAU) in depressed
older patients, we estimate the effect size for depression
outcome of BA versus TAU to be 0.50, a modest but
clinically relevant value. Based on this estimate
(alpha = 0.05, power (beta) = 0.80, 2-tailed test) and data
clustering within PCCs (ICC of 0.05 and a cluster size of
n = 6) 100 patients are required per group with two
groups of 14 clusters (based on 14 potential patients per
PCC and a 50% refusal and a 20% dropout rate).
Recruitment
Several general practices in the South-Eastern region of
the Netherlands are recruited to participate in the study.
General practitioners and mental health nurses are
responsible of the recruitment of participants.
Assignment of interventions
PCCs are the units of randomization. PCCs that employ
the same MHN will be in the same treatment condition,
preventing contamination. An independent statistician
will use pairwise matching to randomize the PCCs,
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taking into account the amount of MHNs in a PCC, as
well as the sex of the MHN and the size of the patient
population. In half of the PCCs the MHNs are trained to
give BA-treatment while the other half will treat patients
as usual. GPs, patients and MHNs are not blinded to
treatment condition because PCCs are the units of
randomisation, but the research assistants that assess
depression after treatment are blind to condition.
Data management
Data are handled confidentially as each patient is coded
with a number. The link between the patient code and
patient information is preserved in a digital document
that will be protected by a password. This document is
only available to the principal investigator, the executive
researcher and the two research assistants. Coded
patient data are kept in a folder that is stored within a
different section of the RadboudUMC database than the
source data. Informed consent forms are kept in a
locked closet, separated from the paper and pencil ques-
tionnaires that also will be archived in a locked closet.
Digital data are stored in Castor EDC, a program with a
built in audit trail. Patients will send the filled in ques-
tionnaires by mail or e-mail. A research assistant will
call patients when there is missing information in a
questionnaire, or when a questionnaire is not returned
in time. When a patient does not want to continue in
the study, all the information up until then is used in
the analyses but no additional information is collected.
Statistical analyses
Clinical outcomes
Data analyses include intention-to-treat analyses and
per-protocol analyses. The relative effectiveness of
behavioural activation and treatment as usual will be
analysed using mixed linear regression modelling. In
addition, we will determine the proportion of patients
that show reliable and clinically significant improvement
on the outcome measures, based on the model of Jacobson
and Truax [78, 79]. Relapse (episode of MDD after remis-
sion) and recurrence (episode of MDD after recovery) will
be assessed in the course of follow-up (6, and 12 months)
using survival analysis (Cox proportional hazards regres-
sion). Intention to treat analyses as well as per protocol
analyses will be conducted.
Economic evaluation
The aim of the economic evaluation is to relate the
difference in societal costs between BA and TAU to the
difference in clinical effects. Both a cost-effectiveness
and a cost-utility analysis will be performed with a time
horizon of 12 months. The analysis will be performed in
accordance with the intention-to-treat principle. Missing
cost and effect data will be imputed using multiple
imputation. Bivariate regression models will be used to
estimate cost and effect differences between the groups
while adjusting for relevant confounders. Incremental
cost-effectiveness ratios (ICERs) will be calculated by
dividing the difference in mean total costs between the
two treatment groups by the difference in mean effects.
Bias-corrected accelerated bootstrapping with 5000 rep-
lications will be used to estimate 95% confidence inter-
vals around cost and effect differences, and uncertainty
around the ICERs. Uncertainty surrounding ICERs will
be graphically presented on cost-effectiveness planes.
Cost-effectiveness acceptability curves will also be esti-
mated showing the probability that BA is cost-effective
in comparison with TAU for a range of different ceiling
ratios thereby showing decision uncertainty [80].
Process variables and predictors
To identify mechanisms of change and the magnitude of
the factors involved, both multilevel mediation models
and structural equation models (using path analysis,
such as Latent Difference Score (LDS) Models) will be
used. Predictors (prognostic factors) and moderators
(prescriptive factors) of outcome will be identified using
mixed regression, building on the effectiveness models.
Monitoring
Given the negligible risks of this study, the monitor is an
independent researcher of the Primary and Community
Care department (ELG) of the Radboud University
Medical Centre.
Harms
We will report all Serious Adverse Events (SAEs) to the
sponsor without undue delay after obtaining knowledge
of the events. We will report the SAEs through the web
portal ToetsingOnline to the accredited Medical Ethics
Committee that approved the protocol, within 7 days of
first knowledge for SAEs that result in death or are life
threatening followed by a period of maximum of 8 days
to complete the initial preliminary report. All other
SAEs will be reported within a period of maximum
15 days after the sponsor has first knowledge of the
serious adverse events.
Discussion
The aim of this study is to investigate whether BA will
be more (cost-)effective than TAU for older adults in
primary care. Although BA has been proven to be an ef-
fective treatment for depression in adults, the effective-
ness of BA delivered by MHNs in older adults, as well as
the possible mechanisms of change are not yet clear.
The results of the study can be used to improve the
quality and availability of treatments for depressed older
adults in primary care.
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The main strength of this study is that procedures
followed in this effectiveness trial closely match the daily
practice of PCCs. Therefore the results can be easily
generalized to other PCCs. Furthermore, our BA proto-
col is adapted to a primary care setting, is very easy to
train, and therefore easily implemented in other PCCs
throughout the Netherlands and abroad.
However, this study also has some limitations that will
be taken into account. The main limitation derives from
the fact that patients as well as some research assistants,
GPs and MHNs are not blinded to patient allocation,
due to cluster randomisation. This might influence their
judgement of severity of depression of the patients. To
prevent biased opinions on whether or not patients (still)
have MDD post-treatment, the clinical interview will be
performed by an independent research assistant that will
be blinded to patient allocation.
Furthermore, we realize that the recruitment of
patients in primary care could be challenging [81]. We
are aware of the fact that Lasagna’s law, that states that
medical investigators tend to overestimate the number
of patients available, holds in Dutch primary care
research [82]. It might be difficult for GPs to inform
depressed older adults about the study in their 10 min
sessions. Therefore the only task GPs will have, is to ask
patients whether they may be contacted by a research
assistant to provide them with more information. From
there on, the research assistant will take over.
Lastly, older adults might have difficulties filling in
questionnaires due to physical problems such as visual
impairments, concentration problems or unfamiliarity
with psychological questionnaires. Therefore an inde-
pendent research assistant, blinded to patient allocation,
is available when needed to help patients at home or by
phone with the questionnaires.
If proven effective, BA can be a valuable addition to
current guidelines for the treatment of older adults with
moderate to severe depressive symptoms in primary care.
Abbreviations
BA: Behavioural Activation; BADS: Behavioural Activation for Depression Scale;
BIA: Budget Impact Analysis; BSI − 18: Brief Symptom Inventory-18; CBT: Cogni-
tive Behavioural Therapy; CEA: Cost effectiveness Analysis; DSST: Digit Symbol
Substitution Test; EuroQol-5D-5 L: European Quality of Life Self-report Question-
naire; GP: General Practitioner; IPT: InterPersonal Therapy; M.I.N.I. 5.0.0: Mini
International Neuropsychiatric Interview; MDD: Major Depressive Disorder;
MHN: Mental Health Nurse; MoCA: Montréal Cognitive Assessment scale;
PCC: Primary Care Centre; PHQ-9: Patient Health Questionnaire- 9;
QALYs: Quality-Adjusted Life-Years; QIDS-SR: Quick Inventory of Depressive
Symptomatology; RCT: Randomised Controlled Trial; RRS: Rumination Response
Scale; SRS: Session Rating Scale; TAU: Treatment As Usual; TiC-P: Trimbos and
iMTA questionnaire on Costs associated with Psychiatric illness;
WHODAS: World Health Organization Disability Assessment Schedule 2.0
Acknowledgements
We thank Anouk Peters, Lotte School and Carla Walk for their assistance.
Funding
The study is funded by the Ministry of Health Funding-program for Health
Care Efficiency Research ZonMw (843001606). Prior to granting the funding
by ZonMw extensive peer review during two phases has been carried out.
ZonMw is not involved in the design of the study and does not participate
in the data collection, analysis of the data and writing of the manuscript.
Availability of data and materials
Not applicable, collection of participants and data is still ongoing.
Authors’ contributions
All authors participated in the design of the study. GJH obtained funding. NJ
drafted the manuscript and carries out recruitment and data-collection. GJH,
PL, MJH, ROV, HVM, MP, JS and JB revised the manuscript. All authors have
approved the final manuscript.
Competing interests
The authors declare that they have no competing interests to disclose.
Consent for publication
Not applicable.
Ethics approval and consent to participate
The Medical Ethics Committee of Radboud University Medical Centre (CMO
Arnhem-Nijmegen) (http://www.ccmo.nl/nl/erkende-metc-s/cmo-regio-arnhem-
nijmegen) approved the study protocol. The study is registered at Dutch Clinical
Trial Register (NTR6013). Before written informed consent is obtained all partici-
pants are provided with printed study information and visited for oral explan-
ation of the study.
Sponsor
Institute for Integrated Mental Health Care “Pro Persona”, Nijmegen, the
Netherlands.
Workplan for knowledge transfer and sustainable implementation
The main goal of this study is to change routines in Dutch primary care for
older patients suffering from depression and to increase the availability of
non-medical treatments for late-life depression in primary care. The main
strategy for disseminating the results of this study, apart from congresses
and scientific publications, is the incorporation of the trial results into the
update of the Depression Guideline of the Dutch College of General
Practitioners. Our research project group has direct access to the Dutch GP
Depression Guideline (van Marwijk). The guideline has a national reach and
is primarily directed at general practitioners and primary care nurses.
The activities to actively change clinical practice consist of the initiation of
an ‘implementation working group’, linked to the research group. Members
of this group are patient and general practitioners of the trial sites and of
the health plans paying for the treatment. A patient and professional
member from the Dutch Association of Mental Health Nurses (Landelijke
Vereniging POH-GGZ) will also join this implementation group, as well as a
representative from the Dutch Depression Association (national patient
organization). During the first three years of the study, the research group
will consult the implementation group about barriers and facilitators related
to the introduction BA in primary care centres.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Behavioural Science Institute, Radboud University, Nijmegen, The
Netherlands. 2Department of Primary and Community Care, Radboud
University Medical Centre Nijmegen, Nijmegen, The Netherlands. 3Institute
for Integrated Mental Health Care “Pro Persona, Nijmegen, The Netherlands.
4Department of Clinical Psychology, VU University Amsterdam, Amsterdam,
The Netherlands. 5University Medical Center Groningen, Interdisciplinary
Center for Psychopathology of Emotion regulation (ICPE), University of
Groningen, Groningen, The Netherlands. 6Centre for Primary Care, Institute
for Population Health, University of Manchester, Manchester, UK.
7Department of Health Sciences and EMGO Institute for Health and Care
Research, Faculty of Earth and Life Sciences, VU university Amsterdam,
Janssen et al. BMC Psychiatry  (2017) 17:230 Page 9 of 11
Amsterdam, The Netherlands. 8MOVE Research Institute Amsterdam, Faculty
of Human Movement Sciences, VU University Amsterdam, Amsterdam, The
Netherlands. 9Department of Psychiatry, Radboud University Medical Centre
Nijmegen, Nijmegen, The Netherlands.
Received: 29 May 2017 Accepted: 16 June 2017
References
1. Luppa M, et al. Age- and gender-specific prevalence of depression in latest-
life–systematic review and meta-analysis. J Affect Disord. 2012;136(3):212–21.
2. Riedel-Heller SG, Busse A, Angermeyer MC. The state of mental health in
old-age across the 'old' European Union– a systematic review. Acta
Psychiatr Scand. 2006;113(5):388–401.
3. Licht-Strunk E, et al. Prevalence of depression in older patients consulting
their general practitioner in The Netherlands. International journal of
geriatric psychiatry. 2005;20(11):1013–9.
4. Stek M, et al. Prevalence, correlates and recognition of depression in the
oldest old: the Leiden 85-plus study. J Affect Disord. 2004;78(3):193–200.
5. Burroughs H, et al. 'Justifiable depression': how primary care professionals
and patients view late-life depression? A qualitative study. Fam Pract.
2006;23(3):369–77.
6. Chew-Graham C, et al. Why may older people with depression not present
to primary care? Messages from secondary analysis of qualitative data.
Health Soc Care Community. 2012;20(1):52–60.
7. Mackenzie CS, Pagura J, Sareen J. Correlates of perceived need for and use
of mental health services by older adults in the collaborative psychiatric
epidemiology surveys. Am J Geriatr Psychiatry. 2010;18(12):1103–15.
8. Sirey JA, et al. Perceived stigma as a predictor of treatment discontinuation
in young and older outpatients with depression. Am J Psychiatry.
2001;158(3):479–81.
9. Licht-Strunk E, et al. Outcome of depression in later life in primary care:
longitudinal cohort study with three years' follow-up. BMJ. 2009;338:a3079.
10. Donohue JM, Pincus HA. Reducing the societal burden of depression.
PharmacoEconomics. 2007;25(1):7–24.
11. Greenberg PE, et al. The economic burden of depression in the United
States: how did it change between 1990 and 2000? J Clin Psychiatry.
2003;64(12):1465–75.
12. Thompson D, Richardson E. Current issues in the economics of depression
management. Current psychiatry reports. 1999;1(2):125–34.
13. Calati R, et al. Antidepressants in elderly: metaregression of double-blind,
randomized clinical trials. J Affect Disord. 2013;147(1–3):1–8.
14. Tedeschini E, et al. Efficacy of antidepressants for late-life depression: a
meta-analysis and meta-regression of placebo-controlled randomized trials.
J Clin Psychiatry. 2011;72(12):1660–8.
15. Beekman AT, et al. The natural history of late-life depression: a 6-year
prospective study in the community. Arch Gen Psychiatry. 2002;59(7):
605–11.
16. Wei W, et al. Use of psychotherapy for depression in older adults. Am J
Psychiatry. 2005;162(4):711–7.
17. Wuthrich VM, Frei J. Barriers to treatment for older adults seeking
psychological therapy. Int Psychogeriatr. 2015;27(07):1227–36.
18. Martell, C.R., S. Dimidjian, and R. Herman-Dunn, Behavioral activation for
depression: A clinician's guide. 2013: Guilford Press.
19. Lewinsohn PM. A behavioral approach to depression. Essential papers on
depression. 1974:150–72.
20. Ekers D, et al. Behavioural activation delivered by the non-specialist: phase II
randomised controlled trial. Br J Psychiatry. 2011;198(1):66–72.
21. Ekers D, et al. Cost utility of behavioural activation delivered by the non-
specialist. Br J Psychiatry. 2011;199(6):510–1.
22. Lemmens LH, et al. Clinical effectiveness of cognitive therapy v.
interpersonal psychotherapy for depression: results of a randomized
controlled trial. Psychol Med. 2015:1–16.
23. Dimidjian S, et al. Randomized trial of behavioral activation, cognitive
therapy, and antidepressant medication in the acute treatment of adults
with major depression. J Consult Clin Psychol. 2006;74(4):658–70.
24. Richards DA, et al. Cost and outcome of Behavioural activation versus
cognitive Behavioural therapy for depression (COBRA): a randomised,
controlled, non-inferiority trial. Lancet. 2016;388(10047):871–80.
25. Jacobson NS, et al. A component analysis of cognitive-behavioral treatment
for depression. J Consult Clin Psychol. 1996;64(2):295.
26. Houtjes W, et al. Unmet needs of outpatients with late-life depression; a
comparison of patient, staff and carer perceptions. J Affect Disord.
2011;134(1–3):242–8.
27. Cuijpers P, van Straten A, Warmerdam L. Behavioral activation treatments of
depression: a meta-analysis. Clin Psychol Rev. 2007;27(3):318–26.
28. Ekers D, Richards D, Gilbody S. A meta-analysis of randomized trials of
behavioural treatment of depression. Psychol Med. 2008;38(5):611–23.
29. Ekers D, et al. Behavioural activation for depression; an update of
meta-analysis of effectiveness and sub group analysis. PLoS One.
2014;9(6):e100100.
30. Cuijpers P, et al. Managing depression in older age: psychological
interventions. Maturitas. 2014;79(2):160–9.
31. Pinquart M, Duberstein P, Lyness J. Effects of psychotherapy and other
behavioral interventions on clinically depressed older adults: a meta-
analysis. Aging Ment Health. 2007;11(6):645–57.
32. Acierno R, et al. Behavioral activation and therapeutic exposure for
bereavement in older adults. American Journal of Hospice and Palliative
Medicine. 2011:1049909111411471.
33. Yon A, Scogin F. Behavioral activation as a treatment for geriatric
depression. Clin Gerontol. 2008;32(1):91–103.
34. Riebe G, et al. Activity scheduling as a core component of effective care
management for late-life depression. Int J Geriatr Psychiatry.
2012;27(12):1298–304.
35. Gilbody S, et al. Effect of collaborative care vs usual care on depressive
symptoms in older adults with subthreshold depression: the CASPER
randomized clinical trial. JAMA. 2017;317(7):728–37.
36. Rosenzweig S. Some implicit common factors in diverse methods of
psychotherapy. Am J Orthopsychiatry. 1936;6(3):412.
37. Lemmens LH, et al. Mechanisms of change in psychotherapy for depression:
an empirical update and evaluation of research aimed at identifying
psychological mediators. Clin Psychol Rev. 2016;50:95–107.
38. Dimidjian S, et al. The origins and current status of behavioral activation
treatments for depression. Annu Rev Clin Psychol. 2011;7:1–38.
39. Santos MM, et al. A client-level session-by-session evaluation of behavioral
activation’s mechanism of action. J Behav Ther Exp Psychiatry. 2017;54:93–100.
40. Papageorgiou, C. and A. Wells, Depressive rumination: Nature, theory and
treatment. 2004: John Wiley & Sons.
41. Cacioppo JT, et al. Loneliness as a specific risk factor for depressive
symptoms: cross-sectional and longitudinal analyses. Psychol Aging.
2006;21(1):140.
42. Netz, Y., et al., Physical activity and psychological well-being in advanced
age: a meta-analysis of intervention studies. 2005, American Psychological
Association.
43. Krell, H.V., et al., Subject expectations of treatment effectiveness and
outcome of treatment with an experimental antidepressant. The Journal of
clinical psychiatry, 2004.
44. Magnée T, et al. Verlicht de POH-GGZ de werkdruk van de huisarts? Ned
Tijdschr Geneeskd. 2016;160(D983):D983.
45. Schulz KF, Grimes DA. Get in the spirit with SPIRIT 2013: protocol content
guideline for clinical trials. Contraception. 2013;88(6):676.
46. Kanter JW, et al. What is behavioral activation?: a review of the empirical
literature. Clin Psychol Rev. 2010;30(6):608–20.
47. Van Marwijk, H., et al., NHG-Standaard Depressieve stoornis (depressie), in
NHG-Standaarden 2009. 2009, Springer. p. 521–537.
48. Rush AJ, et al. The 16-item Quick Inventory of depressive Symptomatology
(QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric
evaluation in patients with chronic major depression. Biol Psychiatry.
2003;54(5):573–83.
49. Sheehan DV, et al. The MINI-International Neuropsychiatric interview (MINI):
the development and validation of a structured diagnostic psychiatric
interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59:22–33.
50. Cameron IM, et al. Measuring depression severity in general practice:
discriminatory performance of the PHQ-9, HADS-D, and BDI-II. Br J Gen
Pract. 2011;61(588):e419–26.
51. Cameron IM, et al. Psychometric comparison of PHQ-9 and HADS for measuring
depression severity in primary care. Br J Gen Pract. 2008;58(546):32–6.
52. Rodda J, Walker Z, Carter J. Depression in older adults. BMJ. 2011;343:d5219.
53. Sheehan, D., et al., MINI-Mini International Neuropsychiatric Interview-
English Version 5.0. 0-DSM-IV. J Clin Psychiatry, 1998. 59: p. 34–57.
54. Lamers LM, et al. The Dutch tariff: results and arguments for an effective
design for national EQ-5D valuation studies. Health Econ. 2006;15(10):1121–32.
Janssen et al. BMC Psychiatry  (2017) 17:230 Page 10 of 11
55. Versteegh MM, et al. Dutch tariff for the five-level version of EQ-5D. Value
Health. 2016;19(4):343–52.
56. Herdman M, et al. Development and preliminary testing of the new five-
level version of EQ-5D (EQ-5D-5L). Qual Life Res. 2011;20(10):1727–36.
57. Hakkaart-van Roijen, L., et al., Trimbos/iMTA questionnaire for costs
associated with psychiatric illness (TIC-P). Institute for Medical Technology
Assessment, Erasmus University Rotterdam. Trimbos, 2002.
58. De Beurs E. Brief symptom Inventory (BSI) en BSI 18. Hand. 2011;2011
59. Meijer RR, de Vries RM, van Bruggen V. An evaluation of the brief symptom
Inventory-18 using item response theory: which items are most strongly
related to psychological distress? Psychol Assess. 2011;23(1):193–202.
60. Petkus AJ, et al. Evaluation of the factor structure and psychometric
properties of the brief symptom Inventory-18 with homebound older
adults. Int J Geriatr Psychiatry. 2010;25(6):578–87.
61. Üstün, T.B., Measuring health and disability: manual for WHO disability
assessment schedule WHODAS 2.0. 2010: World Health Organization.
62. Üstün TB, et al. Developing the World Health Organization disability
assessment schedule 2.0. Bull World Health Organ. 2010;88(11):815–23.
63. Nasreddine ZS, et al. The Montreal cognitive assessment, MoCA: a brief
screening tool for mild cognitive impairment. J Am Geriatr Soc.
2005;53(4):695–9.
64. Kanter JW, et al. The behavioral activation for depression scale (BADS):
psychometric properties and factor structure. J Psychopathol Behav Assess.
2006;29(3):191–202.
65. Nolen-Hoeksema S. The role of rumination in depressive disorders and
mixed anxiety/depressive symptoms. J Abnorm Psychol. 2000;109(3):504.
66. Schoofs H, Hermans D, Raes F. Brooding and reflection as subtypes of
rumination: evidence from confirmatory factor analysis in nonclinical
samples using the Dutch ruminative response scale. J Psychopathol Behav
Assess. 2010;32(4):609–17.
67. Raes F, et al. The Dutch version of the behavioral activation for depression
scale (BADS): psychometric properties and factor structure. J Behav Ther Exp
Psychiatry. 2010;41(3):246–50.
68. van Schooten KS, et al. Assessing physical activity in older adults: required
days of trunk accelerometer measurements for reliable estimation. J Aging
Phys Act. 2015;23(1):9–17.
69. Rispens SM, et al. Consistency of gait characteristics as determined from
acceleration data collected at different trunk locations. Gait Posture.
2014;40(1):187–92.
70. Paraschiv-Ionescu, A., et al., Barcoding human physical activity to assess
chronic pain conditions. PLoS One, 2012. 7(2).
71. De Jong Gierveld J, Van Tilburg T. The De Jong Gierveld short scales for
emotional and social loneliness: tested on data from 7 countries in the UN
generations and gender surveys. Eur J Ageing. 2010;7(2):121–30.
72. Duncan BL, et al. The session rating scale: preliminary psychometric
properties of a “working” alliance measure. Journal of brief Therapy.
2003;3(1):3–12.
73. Hoyer WJ, et al. Adult age and digit symbol substitution performance: a
meta-analysis. Psychol Aging. 2004;19(1):211–4.
74. Golden C. Stroop color and word test: a manual for clinical and
experimental uses. Chicago: Stoelting. Inc.; 1978.
75. Stroop JR. Studies of interference in serial verbal reactions. J Exp Psychol.
1935;18(6):643.
76. Deviliy, G.J. T.D. Borkovec, Psychometric properties of the credibility/
expectancy questionnairefi.
77. Devilly GJ, Borkovec TD. Psychometric properties of the credibility/
expectancy questionnaire. J Behav Ther Exp Psychiatry. 2000;31(2):73–86.
78. Jacobson NS, Truax P. Clinical significance: a statistical approach to defining
meaningful change in psychotherapy research. J Consult Clin Psychol.
1991;59(1):12.
79. Evans C, Margison F, Barkham M. The contribution of reliable and clinically
significant change methods to evidence-based mental health. Evidence
Based Mental Health. 1998;1(3):70–2.
80. Fenwick E, O'Brien BJ, Briggs A. Cost-effectiveness acceptability curves–facts,
fallacies and frequently asked questions. Health Econ. 2004;13(5):405–15.
81. Rengerink KO, et al. Improving participation of patients in clinical trials-
rationale and design of IMPACT. BMC Med Res Methodol. 2010;10(1):85.
82. van der Wouden JC, et al. Survey among 78 studies showed that Lasagna's
law holds in Dutch primary care research. J Clin Epidemiol. 2007;60(8):819–24.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Janssen et al. BMC Psychiatry  (2017) 17:230 Page 11 of 11
